Anti-CD277 antibodies
US11904004B2 · kind B2 · utility
0Cited by
1References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 9, 2020 |
| Grant date | Feb 20, 2024 |
| Priority date | — |
| Expiry date | Oct 6, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.